Obesity is a powerful risk factor for cardiovascular events, but accumulating data suggest that patients can remodel their hearts and improve health outcomes by losing weight.

A 27-year-old woman attends your practice regularly. She is morbidly obese, with a body mass index (BMI) of 47 kg/m². Her comorbidities include hypertension, for which you have commenced her on perindopril 5 mg daily, and newly diagnosed atrial fibrillation (AF), for which you have prescribed metoprolol 25 mg twice daily. You are considering referring her to a cardiologist for possible cardiac ablation (pulmonary vein isolation).

What is the significance of this patient’s morbid obesity in terms of elevating her cardiovascular (CV) risk? What is the connection between her morbid obesity and her other comorbidities? If she were able to lose weight now, would she be able to reverse her CV risk profile and alleviate her current comorbidities? What options are available for weight loss?
Obesity in Australia

Australia, like all other developed countries, is experiencing a ballooning epidemic of obesity. The majority of our population is now overweight or obese (Table 1), with a fourfold increase in obesity having occurred over the past 30 years.\(^1\) The largest increase has occurred in the group of individuals who are ‘morbidly obese’, equating to a body mass index (BMI) of 40 kg/m\(^2\) or above. Consequently many obesity researchers have begun to use additional classifications such as ‘super obese’ (BMI ≥50 kg/m\(^2\)) and ‘super-super obese’ (BMI ≥60 kg/m\(^2\)).\(^2\)

The rise in morbid obesity impacts heavily on the Australian economy, with annual costs calculated at $58 billion.\(^3\) This figure includes direct healthcare costs for morbid obesity and its known complications, disability pension costs and loss of productivity. In the Global Burden of Disease Study, obesity was identified as the strongest contributor to the burden of disease for modern Australasia.\(^4\)

In many ways, the epidemic of obesity in the 21st century evokes the epidemic of smoking in the 20th century. Both are culturally-dependent epidemics, and both obesity and smoking are powerful modifiable risk factors for CV events. Despite the common misperception, morbid obesity is in fact a significantly stronger risk factor for premature myocardial infarction than smoking.\(^5\) Highly successful public health campaigns significantly reduced the prevalence of cigarette smoking; health organisations and doctors will need to campaign against environmental factors enabling obesity in a similar manner to promote national CV health. Food companies may resist (like cigarette companies), with advertising of unhealthy foods, promotion of such foods to children, and sponsoring of events.

Obesity and cardiovascular risk

Physiology

The impact of obesity on CV risk is multifactorial and self-amplifying. Obesity augments CV risk by multiple mechanisms, as illustrated in the flowchart. The direct mechanical effect of excess adipose tissue increases total body blood volume, cardiac filling pressures and sympathetic activation, leading to an increased cardiac workload and cardiac hypertrophy. Adipose tissue also increases cardiac afterload and chest-wall resistance, enabling the development of both systemic hypertension and obstructive sleep apnoea.\(^6\)

Adipose tissue is more than just a mechanical load, however, creating a web of metabolic consequences. It is very active metabolically, both in synthesising and in metabolising numerous substances. These substances are predominantly pro-inflammatory and prothrombotic (tumour necrosis factor-alpha, interleukin-6, plasminogen activator inhibitor 1, oestrogen) or worsen insulin resistance and lipid

### Table 1. Obesity in Australia

<table>
<thead>
<tr>
<th>Category</th>
<th>Body mass index (kg/m(^2))</th>
<th>Australian population (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underweight</td>
<td>&lt;20</td>
<td>1.7</td>
</tr>
<tr>
<td>Normal weight</td>
<td>20 to &lt;25</td>
<td>35.5</td>
</tr>
<tr>
<td>Overweight</td>
<td>25 to &lt;30</td>
<td>35.3</td>
</tr>
<tr>
<td>Obese</td>
<td>≥30</td>
<td>27.5</td>
</tr>
<tr>
<td>- Morbidly obese</td>
<td>40 to &lt;50</td>
<td></td>
</tr>
<tr>
<td>- Super obese</td>
<td>50 to &lt;60</td>
<td></td>
</tr>
<tr>
<td>- Super super obese</td>
<td>≥60</td>
<td></td>
</tr>
</tbody>
</table>

### Mechanisms by Which Obesity Augments Cardiovascular Risk

- **Obesity**
  - Mechanical effects of increased weight on chest wall (epicardial and visceral fat)
  - Proinflammatory prothrombotic state
  - Association with components of the metabolic syndrome, increased insulin resistance
  - Hypertension, dyslipidaemia, diabetes
  - Acute coronary syndromes
  - Heart failure
  - Left heart hypertrophy
  - Obesity cardiomyopathy ‘adipositas cordis’
  - Atrial fibrillation
  - Restrictive cardiac filling pattern
  - Increased cardiac workload
  - Obstructive sleep apnoea

---

\(^{1}\) Source: Australian Bureau of Statistics

\(^{2}\) Source: World Health Organization

\(^{3}\) Source: Commonwealth Department of Health

\(^{4}\) Source: Global Burden of Disease Study

\(^{5}\) Source: Australian Medical Association

\(^{6}\) Source: Obesity Australia
metabolism (leptin, adiponectin, insulin-like growth factor, insulin-binding protein).7

Clinical events
The physiological effects of obesity directly elevate the risks of multiple cardiac conditions (Table 2).8-17 Hypertension and dyslipidaemia are widely prevalent in obese patients, and the association of hypertension, dyslipidaemia and central obesity has been formally recognised in ‘the metabolic syndrome’. Type 2 diabetes is also strongly associated with obesity, which has led to the coining of the term ‘diabesity’.18

The combination of cardiac hypertrophy and direct fatty infiltration creates a substrate for arrhythmias. The most common arrhythmia observed is AF, and the dose-dependent link between obesity and AF is now well established. Pathak and colleagues have quoted an increased risk of 3 to 7% for developing AF for each incremental unit of BMI.14

Patients who are obese also have an elevated incidence of ventricular dysrhythmias, raising the risk of sudden cardiac death.19 Obesity is now the leading cause of nonischaemic sudden cardiac death in young people,17,20 responsible for approximately 25% of cases. Cardiopulmonary resuscitation is more difficult in those who are obese, potentially further compromising outcomes.

A 2008 study of more than 100,000 patients with acute coronary syndromes demonstrated that morbid obesity is now the most powerful risk factor for premature CV events, lowering the age of first coronary syndrome by a mean of 12 years.5 By contrast, smoking lowered the age of first coronary syndrome by a mean of only 9.7 years.5

With an increasing morbidly obese population, cardiologists are seeing an increase in young patients with ST-segment elevation infarctions (STEMIs). A 2011 study into the high prevalence of obesity in young patients with STEMIs found that almost 80% of young patients (men aged less than 45 years, women less than 55 years) who experienced a STEMI were obese.16

Appreciation of the adverse effects of obesity has driven new recommendations in societal guidelines. For instance, in the most recent NHMRC guidelines on the management of obesity, doctors are now strongly advised to inform their patients who are obese of their elevated CV risk profile and mortality (Table 3).9

### TABLE 2. CARDIAC COMPLICATIONS OF OBESITY AND THEIR REVERSIBILITY

<table>
<thead>
<tr>
<th>Cardiac complication</th>
<th>How obesity causes/exacerbates complication</th>
<th>Impact of obesity on risk (quoted in literature)</th>
<th>Endpoints improved by weight loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hypertension</td>
<td>Elevated afterload</td>
<td>50% prevalence of hypertension in obese subjects8</td>
<td>Medication requirement May be treated by weight loss8,10</td>
</tr>
<tr>
<td></td>
<td>Increased total body water and salt levels</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Increased sympathetic activity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyslipidaemia</td>
<td>Abnormal production of triglycerides and LDL cholesterol</td>
<td>4 x risk11</td>
<td>HDL/LDL cholesterol ratio9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Medication requirement May be treated by weight loss10</td>
</tr>
<tr>
<td>Type 2 diabetes</td>
<td>Insulin resistance created by metabolic effects of adipose tissue</td>
<td>5.8 x risk12</td>
<td>Medication requirement10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HbA1c10 Risk of developing diabetes (reduced by 30-60%)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>Increased epicardial fat deposition and fatty infiltration in association with increased prevalence of hypertension and sleep apnoea causing electrostructural dysfunction</td>
<td>2.03 x risk13</td>
<td>Left atrial volume Epiperal fat volume on cardiac MRI (reduced)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dose-dependent relationship: up to 7% increased risk of AF per incremental unit of BMI14</td>
<td>Burden of AF may be treated with weight loss14</td>
</tr>
<tr>
<td>Acute coronary syndrome</td>
<td>Increased atheromatous plaque formation increased myocardial demand with excess adipose tissue Increased prevalence of risk factors such as hypertension, dyslipidaemia, type 2 diabetes</td>
<td>Morbid obesity lowers age of first NSTEMI by 12 years9</td>
<td>Cardiovascular events and death (reduced)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>80% prevalence of obesity in young patients with a STEMI16</td>
<td></td>
</tr>
<tr>
<td>Sudden cardiac death</td>
<td>Fatty infiltration creating substrate for ventricular dysrhythmias Cardiomyopathy</td>
<td>2.6 x increased risk in obese men, 5.8 x increased risk in obese women17</td>
<td>No available data showing weight loss decreases cardiac arrest</td>
</tr>
</tbody>
</table>

Abbreviations: AF = atrial fibrillation; HbA1c = glycated haemoglobin; HDL = high density lipoprotein; LDL = low density lipoprotein; MRI = magnetic resonance imaging; NSTEMI = non-ST-segment elevation infarction; STEMI = ST-segment elevation infarction.
Morbid obesity and procedural complications and outcomes

Despite typically being younger, morbidly obese patients with coronary syndromes are prone to increased procedural complications and poorer outcomes than normal weight patients. Cardiac work-up of obese patients is problematic, both in the difficulty of these patients exercising and in the poor image quality achieved across a range of investigational modalities. The ECG from such patients often has baseline abnormalities that obscure correct interpretation (for example, axis deviation or diffusely low QRS voltages). In addition, false-positive results suggesting ischaemia have been recorded at higher frequency for morbidly obese patients undergoing echocardiography, stress echocardiography and stress thallium testing.

Coronary angiography may be particularly hazardous for obese patients, with complication rates significantly in excess of those experienced by normal weight patients. The Blue Cross Blue Shield of Michigan Cardiovascular Consortium registry is one of the largest registries from which CV outcomes in morbidly obese patients have been assessed. In 2013, analysis of data from 227,044 patients in the registry undergoing percutaneous coronary intervention revealed that compared with overweight patients, morbidly obese patients experienced more vascular complications, almost twice the rate of contrast-induced nephropathy, a fourfold increased risk of contrast nephropathy requiring dialysis, and an increased risk of mortality (odds ratio, 1.63). This increased risk of mortality has been confirmed in other publications. Other problematic elements of coronary angiography include three to four times the typical quantity of radiation exposure, increased contrast use and lengthened procedure time.

For morbidly obese patients requiring cardiothoracic surgery, risks remain elevated above baseline. Australian data suggest that morbid obesity is associated with prolonged ventilation, deep sternal wound infection, renal failure, return to intensive care and longer length of hospital stay. International studies have confirmed these elevated risks and associated increased costs, and have stated that the increased number of obese patients undergoing cardiothoracic surgery ‘demands attention’.

Can cardiovascular morbidity be reversed by weight loss?

It can be dispiriting to connect the links between increased CV risk in obesity and consequent worsened outcomes. It may appear that all obese patients are on a one-way journey of worsened health outcomes; however, data increasingly suggest that patients can remodel their hearts and health outcomes by losing weight. Some
of the most powerful data in this area are Australian and may ultimately dramatically shape future guidelines on CV care of the obese. GPs will have a key role in this new paradigm of obese CV care (Table 3).

It is increasingly being recognised that successful weight loss may alleviate the 'metabolic syndrome', with reductions in hypertension, dyslipidaemia and insulin resistance. One of the most powerful trials to date bearing out this association was the recent STAMPEDE (Surgical Treatment And Medications Potentially Eradicate Diabetes Effectively) trial.\textsuperscript{30} In this trial, published in The New England Journal of Medicine in 2012, 150 obese patients with type 2 diabetes mellitus received either medical treatment for their obesity or a combination of surgical (gastric bypass or sleeve gastrectomy) and medical treatment. Although external validity is limited by its nature as a single-centre, nonblinded study, results were highly significant. Patients in the combined surgical and medical arm of the trial lost an average of 27 kg of weight over 12 months. This weight loss was associated with mean improvement in HbA\textsubscript{1c} from 9.4% to 6.5%, a 28.4% improvement in HDL cholesterol readings, and a 43% improvement in triglyceride levels. Particularly impressive was the significant reduction in patients' requirement for diabetic medications and lipid-lowering, antihypertensive and antithrombotic agents following surgery. These outcomes, including the degree of weight loss, were largely sustained at the three-year follow up in 2014.\textsuperscript{10}

**TABLE 3. MANAGING OBESITY IN PATIENTS BASED ON NHMRC RECOMMENDATIONS**

<table>
<thead>
<tr>
<th>Process</th>
<th>Recommendation</th>
<th>NHMRC grade*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Identifying obesity</td>
<td>Calculate patient’s body mass index (BMI)</td>
<td>B</td>
</tr>
<tr>
<td></td>
<td>Use waist circumference to further stratify risk of obesity-related comorbidities</td>
<td>C</td>
</tr>
<tr>
<td>2. Counselling</td>
<td>Discuss readiness to change lifestyle behaviours with adults who are overweight or obese</td>
<td>D</td>
</tr>
<tr>
<td></td>
<td>Strongly advise that modest weight loss reduces cardiovascular risk factors. Strongly advise patients with prediabetes or diabetes that health benefits of modest weight loss include prevention, delayed progression or improved control of type 2 diabetes</td>
<td>A</td>
</tr>
<tr>
<td>3. Recommending lifestyle changes</td>
<td>Strongly recommend lifestyle change to adults who are overweight or obese. Such lifestyle measures include reduced energy intake, increased physical activity and measures to support behavioural change</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>Prescribe a diet to achieve reduced calorie intake: for overweight/obese adults, target a 2500 kJ/day energy deficit and tailor programs to the individual’s dietary preferences</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>Approximately 300 minutes of moderate intensity activity, or 150 minutes of vigorous activity, each week combined with reduced dietary intake should be recommended for adults who are overweight or obese</td>
<td>CBR</td>
</tr>
<tr>
<td></td>
<td>A self-management approach should be included in a weight management program</td>
<td>C</td>
</tr>
<tr>
<td></td>
<td>Active weight management in adults should involve a fortnightly review for the first three months. Monitoring should be continued for at least 12 months and additional intervention included as required</td>
<td>B</td>
</tr>
<tr>
<td>4. Recommending additional interventions</td>
<td>Orlistat may be considered as an adjunct to lifestyle interventions in adults with BMI ≥30 kg/m\textsuperscript{2}, or adults with a BMI ≥27 kg/m\textsuperscript{2} and comorbidities. The individual situation must be taken into account</td>
<td>A</td>
</tr>
<tr>
<td></td>
<td>Referral to a bariatric surgeon for assessment of suitability for bariatric surgery may be considered in adults with a BMI &gt;40 kg/m\textsuperscript{2}, or in those with a BMI &gt;35 kg/m\textsuperscript{2} and comorbidities that may improve with weight loss. The individual situation must be taken into account</td>
<td>A</td>
</tr>
</tbody>
</table>

* NHMRC recommendation grades: A = body of evidence can be trusted to guide practice; B = body of evidence can be trusted to guide practice in most situations; C = body of evidence provides some support for recommendation(s) but care should be taken in its application; D = body of evidence is weak and must be applied with caution; CBR = consensus-based recommendation formulated in the absence of quality evidence.
and insulin requirements. In some cases, weight loss appeared to have induced complete remission of these conditions, with remission sustained for at least three years’ follow up. A South Australian cardiac team has provided further support for the key role of weight loss in improving CV health, this time in the context of AF. As described earlier, AF may be mechanistically linked to systemic hypertension, cardiac hypertrophy, fatty infiltration of cardiac muscle and altered electrical conduction. Pathak and colleagues have shown that weight loss has a dose-dependent effect in reducing patients’ burden of AF.31 Patients who were able to lose more than 10% of their body weight had a sixfold greater probability of remaining free from AF. This reduction in AF has also been shown to be associated with structural improvements in cardiac measurements, with partial reversal of pathological cardiac remodelling.32

There are also increasing data suggesting that even established coronary artery disease may be attenuated or reversed by weight loss. In one observational study, patients who achieved sustained weight loss with Roux-en-Y bypass had reduced coronary calcification compared with obese patients, and assessment of atherosclerotic carotid plaque patterns showed a similar trend.33 In the Swedish Obese Subjects study in 2012, the risk of CV events and death was significantly reduced in obese patients who underwent bariatric surgery compared with obese control subjects receiving usual care (hazard ratio, 0.67).15 It is worth noting, however, that in post-hoc statistical analysis, risk reduction was not able to be definitively linked with the observed weight loss; the authors suggested a range of possible reasons, including underpowering.

**How can morbidly obese patients lose weight?**

Weight loss appears increasingly to be one of our most powerful weapons against CV disease. However, achieving and sustaining significant weight loss is not easy. It is believed that a complex interplay of genetics, epigenetics, diet, exercise and shifting cultural patterns have led to the current ‘obesity epidemic’. Despite recognition of the rewarding benefits of weight loss, it is not possible to reverse all predisposing factors (i.e. strong genetic factors, possible in utero effects) for obesity.

Practically, it is usually not feasible for morbidly obese patients to participate in regular exercise programs to an adequate degree to achieve weight loss. Thus far, antiobesity medications have been of limited benefit largely because of side effects and are not yet a long-term solution.34

Obesity surgery is hence emerging as an increasingly popular first step to weight loss in the morbidly obese population, and is likely to become more available to Australians. Government bodies are now recognising it as a cost-effective intervention, and, as mentioned above, its ability to improve health outcomes was clearly demonstrated in the STAMPEDE trial. Accumulating evidence from prospective trials has shown that various forms of bariatric surgery may have positive impacts on CV endpoints.

Table 3 outlines a suggested approach for doctors involved in the care of obese patients, based on the 2013 NHMRC’s *Clinical Practice Guidelines for the Management of Overweight and Obesity in Adults, Adolescents and Children in Australia.*9 Within these and other international guidelines, the role of referral for consideration of bariatric surgery is increasingly being emphasised, particularly for patients with comorbidities that are identifiable as obesity-related. Assessment before such surgery is essential and lifetime follow up afterwards is necessary as nutritional deficiencies and other side effects must be minimised.

**Conclusion**

Morbid obesity is increasingly common in Australia today. GPs are likely to have many morbidly obese patients in their practices who have associated comorbidities. It is important that doctors and patients appreciate how powerfully morbid obesity amplifies the risks of premature CV events, and that it is in fact an even stronger risk factor than smoking.

Morbidly obese patients are likely to have many CV comorbidities, and hence earlier cardiac events. When they experience cardiac events and interventions, they are at risk of significantly worse clinical outcomes.

Reversal of morbid obesity, happily, appears to be a potent intervention for reversing the burden of disease experienced by the morbidly obese. Cardiac comorbidities may be alleviated by weight loss, and medication requirement may be significantly reduced.

Alongside counselling patients sympathetically about diet and suitable exercise, GPs will increasingly be able to expedite referrals for obesity intervention to help optimise the CV risk profile of obese patients.

**References**

A list of references is included in the website version (www.medicinetoday.com.au) and the iPad app version of this article.

---

**COMPETING INTERESTS:** None.
References


